C5a receptor modulators

A compound of formula (I)

• wherein
• ring A represents a saturated 4- to 7-membered mono-cyclic carbocyclic ring containing the ring nitrogen atom to which R1 is attached, wherein said ring independently is unsubstituted, or mono-, or di-substituted wherein the substituents are independently selected from (C1-3)alkyl, fluoro, or (C1-4)alkoxy-carbonyl;
• or
• ring A represents a saturated 7- or 8-membered bridged bi-cyclic carbocyclic ring containing the ring nitrogen atom to which R1 is attached, wherein said ring is unsubstituted;
• X and Z independently represent CR5 or N;
• and Y represents CR5;
• or, in case both X and Z represent CH, Y may in addition represent N;
• wherein each R5 independently represents hydrogen, or (C1-3)alkyl;
• R1 represents
• (C1-4)alkyl;
• —CO—R11 wherein R11 represents (C1-4)alkyl;
• (C1-4)alkoxy;
• phenyl, phenoxy;
• (C3-6)cycloalkyl;
• or (C3-6)cycloalkoxy optionally containing one ring oxygen and optionally mono-substituted with methyl or trifluoromethyl;
• benzyl wherein the phenyl ring of said benzyl is optionally mono- or di-substituted with halogen;
• or
• phenyl, or 5- or 6-membered heteroaryl;
• wherein said phenyl or 5- or 6-membered heteroaryl independently is unsubstituted, mono-, di- or tri-substituted, wherein the substituents are independently selected from
• (C1-4) alkyl;
• (C1-4)alkoxy;
• (C1-3)fluoroalkyl;
• (C1-3)fluoroalkoxy;
• halogen;
• cyano;
• nitro;
• hydroxy;
• hydroxy-(C1-3)alkyl;
• (C1-4)alkoxy-(C1-3)alkyl;
• hydroxy-(C2-3)alkoxy;
• (C1-4)alkoxy-(C2-3)alkoxy;
• (C3-6)cycloalkyl-X12—, wherein X12 represents a direct bond, —O—, or —(C1-3)alkylene-O—, and wherein the (C3-6)cycloalkyl independently contains one optional ring oxygen;
• R13—CO—X13—, wherein X13 represents a direct bond or (C1-3)alkylene, and R13 represents hydrogen or (C-4)alkyl);
• 3-(morpholin-4-yl)-prop-1-ynyl;
• R14aR14bN—X14—, wherein X14 represents a direct bond or (C1-3)alkylene;
• and wherein R14a and R14b independently represent hydrogen, (C1-4)alkyl, hydroxy-(C2-4)alkyl, (C1-3)alkoxy-(C2-4)alkyl;
• or R14a and R14b together with the nitrogen to which they are attached to form a 4- to 6-membered saturated ring optionally containing one additional ring heteroatom selected from oxygen and nitrogen;
• and wherein said ring is optionally mono-substituted with (C1-4)alkyl, hydroxy, (C1-4)alkoxy, or dimethylamino;
• or
• benzyloxy, wherein the phenylring of benzyloxy is optionally mono- or di-substituted with halogen or methyl;
• R2 represents phenyl, or 5- or 6-membered heteroaryl;
• wherein said phenyl or 5- or 6-membered heteroaryl independently is mono-, di- or tri-substituted, wherein the substituents are independently selected from
• (C1-4)alkyl;
• (C1-4)alkoxy;
• (C1-3)fluoroalkyl;
• (C1-3)fluoroalkoxy;
• halogen;
• or
• (C3-6)cycloalkyl-X21—, wherein X21 represents a direct bond, —O—, or —(C1-3)alkylene-O—, and wherein the (C3-6)cycloalkyl independently contains one optional ring oxygen;
• R3 represents hydrogen, or (C1-3)alkyl;
• and
• R4 represents
• (C1-4)alkyl;
• hydroxy-(C1-3)alkyl;
• —O—R41, wherein R41 represents
• hydrogen;
• (C1-4) alkyl;
• (C2-4)alkyl which is substituted with one or two hydroxy;
• R41aR41bN—(C2-3)alkylene-, wherein R41a and R41b independently represent hydrogen or (C1-4)alkyl;
• or
• (C4-7)heterocyclyl-X41—, wherein X41 represents a direct bond or (C1-3)alkylene, and wherein the (C4-7)heterocyclyl independently contains one or two ring heteroatoms independently selected from nitrogen and oxygen;
• wherein said (C4-7)heterocyclyl independently is unsubstituted, or mono-, or di-substituted, wherein the substituents are independently selected from:
• (C1-4)alkyl;
• and/or
• (C1-4)alkoxy-carbonyl attached to a ring nitrogen atom having a free valency;
• NR42aR42b wherein R42a and R42b independently represent hydrogen, (C1-4)alkyl, (C1-3)alkoxy-(C2-3)alkyl, hydroxy-(C2-3)alkyl, or R42a and R42b together with the nitrogen to which they are attached form a 4- to 7-membered saturated ring optionally containing one further ring heteroatom selected from oxygen and nitrogen, wherein said ring is unsubstituted or mono-substituted with (C1-3)alkyl or (C1-3)alkoxy;
• or
• —CO—R43 wherein R43 represents (C1-4)alkoxy, or —NR43aR43b wherein R43a and R43b independently represent hydrogen, (C1-4)alkyl, (C1-3)alkoxy-(C2-3)alkyl or hydroxy-(C2-3)alkyl;
• or a pharmaceutically acceptable salt thereof.